diabetestalk.net

Glycaemic Control In People With Type 2 Diabetes Mellitus During And After Cancer Treatment: A Systematic Review And Meta-analysis

Glycaemic control in people with type 2 diabetes mellitus during and after cancer treatment: A systematic review and meta-analysis

Glycaemic control in people with type 2 diabetes mellitus during and after cancer treatment: A systematic review and meta-analysis

Abstract
Cancer and Diabetes Mellitus (DM) are leading causes of death worldwide and the prevalence of both is escalating. People with co-morbid cancer and DM have increased morbidity and premature mortality compared with cancer patients with no DM. The reasons for this are likely to be multifaceted but will include the impact of hypo/hyperglycaemia and diabetes therapies on cancer treatment and disease progression. A useful step toward addressing this disparity in treatment outcomes is to establish the impact of cancer treatment on diabetes control.
The aim of this review is to identify and analyse current evidence reporting glycaemic control (HbA1c) during and after cancer treatment.
Methods
Systematic searches of published quantitative research relating to comorbid cancer and type 2 diabetes mellitus were conducted using databases, including Medline, Embase, PsychINFO, CINAHL and Web of Science (February 2017). Full text publications were eligible for inclusion if they: were quantitative, published in English language, investigated the effects of cancer treatment on glycaemic control, reported HbA1c (%/mmols/mol) and included adult populations with diabetes. Means, standard deviations and sample sizes were extracted from each paper; missing standard deviations were imputed. The completed datasets were analysed using a random effects model. A mixed-effects analysis was undertaken to calculate mean HbA1c (%/mmols/mol) change over three time periods compared to baseline.
The available literature exploring glycaemic control post-diagnosis was mixed. There was increased risk Continue reading

Rate this article
Total 1 ratings
How Does High Salt/Sodium Intake Affect a Diabetic? | Diabetes Self Caring

How Does High Salt/Sodium Intake Affect a Diabetic? | Diabetes Self Caring


How Does High Salt Intake Affect a Diabetic?
How Does High Salt Intake Affect a Diabetic?
It is a saying that you should take your life with a pinch of salt. But it cant be said in the case of a person suffering from diabetes. It is a known fact that a diabetic should eat everything in moderation. That even includes salt. Excessive usage of salt increases the risk of cardiovascular attack or heart stroke as well. It is expected from people who are diabetic that should cut the sodium intake in their food and that doesnt mean that they should just a tasteless or plain food. Cutting down sodium means cutting down on the canned vegetables , canned soup, salad dressings and cereals. Though the percentage of sodium mentioned on the label may or may not be right, it is still better to avoid things which contain sodium. Being a diabetic one must always keep an eye on sodium intake as people even experience high blood pressure after a salty food intake.
Salt is not known to increase the blood sugar levels but still as a part of a diabetes management program it is best to limit it. Eating salt can lead to high blood pressure levels and which not only increases the risk of heart attacks but also the kidney failure and in severe cases, may even lead to stomach cancer.
There are some tips to help you reduce the intake of salt in your diet
Findings and Research on Risk of High Salt intake linked to Diabetes
There are a few findings from the Institute of Environmental Medicine IMM at Karolinska Institutet in Sweden which have proved to be very beneficial on the subject:
For ever Continue reading

Writing a Section 504 Plan for Diabetes

Writing a Section 504 Plan for Diabetes


by Laura Hieronymus, DNP, MSEd, RN, MLDE, BC-ADM, CDE, FAADE, Alba Morales, MD, and Leslie Scott, PhD, PPCNP-BC, CDE, MLDE
Diabetes is one of the most common chronic illnesses in youth. Approximately 5% of all new diabetes cases are Type 1 , with most of these cases affecting children and adolescents. In fact, more than 18,000 people under age 20 are diagnosed with Type 1 annually. Also of concern is the growing number of new cases of Type 2 diabetes in youth over 5,000 diagnoses annually in the U.S.
As we get ready to head into another school year, it is important that as the parent or guardian of a child with diabetes, you and your childs school have all the information necessary to ensure your child has a successful school year. While about one in every 300 to 350 children has diabetes, that may not be the case in your childs school.
Section 504 of the Rehabilitation Act of 1973, or Section 504, is a federal civil rights law put in place to prevent discrimination of an individual with a disability. It reads, No otherwise qualified individual with a disability in the United Statesshall, solely by reason of her or his disability, be excluded from the participation in, be denied the benefits of, or be subjected to discrimination under any program or activity receiving Federal financial assistance.
Children and adolescents with diabetes are covered under Section 504. Diabetes is considered a disability, defined as a physical or mental impairment that substantially limits one or more major life activities. With diabetes, the inability of the body to keep blood glucose Continue reading

Genome | Personalized Insulin Pumps Help Patients With Type 1 Diabetes

Genome | Personalized Insulin Pumps Help Patients With Type 1 Diabetes


Personalized Insulin Pumps Help Patients With Type 1 Diabetes
Managing type 1 diabetes is a full-time job, one that bears an unrelenting reminder of the chronic disease through daily injections and pinpricks. But a new clinical trial for a personalized intervention could pave the way to easing the burden for patients with diabetes.
Sponsored by Medtronic, the multicenter nationwide trial is testing a first-of-its-kind, FDA-approved system that uses artificial intelligence to monitor and control participants blood glucose levels. Medtronic first released the MiniMed 670G device used in the trial in 2016 after the FDA decided to fast-track the systems approval.
Now, investigators are enrolling patients for the second cohort of Medtronics four-year clinical trial with the aim of having 1,000 subjects complete the study. The trial divides subjects into three cohorts: those currently using insulin pumps but not blood glucose sensors ; those using a pump and a sensor; and those using neither pumps nor sensors.
Linda Aman, a sub-investigator on the trial, has patients who drive several hours to participate at the Grunberger Diabetes Institute, one of the trial sites in Bloomfield Hills, Michigan, for the promise of a more automated insulin delivery system.
Basically what this pump does, it is supposed to reduce the burden of taking care of [type 1] diabetes, Aman says. Its a very high burden. You have to deliver your insulin somehow either with a pump or with injections or you can inhale it. But you have to do all this in contest with what your blood sugars are doing, so yo Continue reading

Pump May Beat Shots for Type 1 Diabetes

Pump May Beat Shots for Type 1 Diabetes


Study found young patients had better blood sugar control with insulin pump, but cost is higher
TUESDAY, Oct. 10, 2017 (HealthDay News) -- In young people with type 1 diabetes, insulin pump therapy may offer better blood sugar control and fewer complications than daily injections of the vital hormone, new German research suggests.
"Insulin pumps work, and they work even somewhat better than multiple daily injections overall," said Dr. Robert Rapaport, chief of the division of pediatric endocrinology at the Icahn School of Medicine at Mount Sinai in New York City.
Dr. Siham Accacha, a pediatric endocrinologist at NYU Winthrop Hospital in Mineola, N.Y., explained why that might be so.
"If the pump is really taken care of, you can micromanage your diabetes," she said. "You can stop the pump if your blood glucose is coming down, or you can give a bit more insulin if it's going up."
Both Rapaport and Accacha prefer pump use, but if patients would rather do multiple daily injections, the doctors said that excellent control can also be maintained with shots. It's really a matter of patient preference, they noted.
One issue with the pump is price. The start-up cost for a pump can be as much as $5,000, according to Accacha. And there are monthly costs for supplies as well. Insurers, especially Medicaid, sometimes hesitate to pay, both experts said. But studies like this latest one help provide more evidence about the importance of pump therapy.
"Pumps are more expensive, but I don't think expense should guide quality of therapy," Rapaport said. "Even though pumps are more e Continue reading

No more pages to load

Popular Articles

Related Articles